WHO prioritizes Regeneron's maftivimab for Bundibugyo ebolavirus trials (simplywall.st)

• WHO prioritizes maftivimab for Bundibugyo ebolavirus trials.
• Maftivimab is a component of Inmazeb, approved for Zaire ebolavirus.
• Regeneron has supplied Inmazeb for previous outbreaks.

"The World Health Organization recommends Regeneron's maftivimab, a component of Inmazeb, for priority evaluation in clinical trials for the current Bundibugyo ebolavirus outbreak. Maftivimab is already approved for Zaire ebolavirus treatment. The recommendation positions Regeneron (NasdaqGS:REGN) within an active emergency response affecting multiple African countries, highlighting the company's ability to repurpose existing antibodies for new outbreaks."